Baricitinib Backed for Approval for Alopecia Areata in the EU Baricitinib Backed for Approval for Alopecia Areata in the EU

In February 2022, the FDA granted priority review for baricitinib in adults with severe alopecia areata.International Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Dermatology News Alert Source Type: news